| scholarly article | Q13442814 |
| P50 | author | Xavier Corbella | Q57305945 |
| P2093 | author name string | Montero A | |
| Ariza J | |||
| Cabellos C | |||
| Doménech A | |||
| Gudiol F | |||
| Ayats J | |||
| Tubau F | |||
| Ardanuy C | |||
| P2860 | cites work | An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. | Q31991277 |
| Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria | Q33735389 | ||
| Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. | Q33970252 | ||
| In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model | Q33976928 | ||
| In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak | Q33979213 | ||
| Activity of Gentamicin, Tobramycin, Polymyxin B, and Colistimethate in Mouse Protection Tests with Pseudomonas aeruginosa | Q34934410 | ||
| Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem | Q35132306 | ||
| Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features | Q35369996 | ||
| In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. | Q35807981 | ||
| Antimicrobial susceptibility of Acinetobacter species | Q35811495 | ||
| Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam | Q39391281 | ||
| Detection of carbapenemase-producing Acinetobacter baumannii in a hospital | Q39455145 | ||
| Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. | Q39461202 | ||
| Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii | Q39476331 | ||
| In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. | Q39476552 | ||
| Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods | Q40180863 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains | Q43552346 | ||
| Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay | Q43798721 | ||
| Epidemiological characterization of hospital-acquired Acinetobacter baumannii isolates from a 1500-bed teaching hospital by phenotypic and genotypic methods | Q44417550 | ||
| A reassessment of the in-vitro activity of colistin sulphomethate sodium | Q50135598 | ||
| Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. | Q51120557 | ||
| In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. | Q54031277 | ||
| Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. | Q54043075 | ||
| National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System | Q56898992 | ||
| Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumannii | Q63197407 | ||
| Automated high-performance liquid chromatographic method for the determination of rifampicin in plasma | Q68226155 | ||
| High-performance liquid chromatographic assay of sulbactam using pre-column reaction with 1,2,4-triazole | Q70093200 | ||
| Effects of aging on antibacterial mechanisms in experimental pneumonia | Q70287885 | ||
| An outbreak of multiresistant Acinetobacter baumanii in a university hospital in São Paulo, Brazil | Q71526515 | ||
| Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenem | Q71586827 | ||
| Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium | Q73506350 | ||
| Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998 | Q73560650 | ||
| Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia | Q73626101 | ||
| Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4-5 November 1996 at Eilat, Israel | Q73713254 | ||
| Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium | Q73821582 | ||
| Acinetobacter species as nosocomial pathogens | Q74659847 | ||
| Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network | Q77387132 | ||
| Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period | Q77931786 | ||
| In-vitro and in-vivo activities of antimicrobial agents against Acinetobacter calcoaceticus | Q93575633 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rifampicin | Q422652 |
| multiple drug resistance | Q643839 | ||
| Acinetobacter baumannii | Q3241189 | ||
| P304 | page(s) | 1946-1952 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii | |
| P478 | volume | 46 |
| Q61805238 | A Porcine Wound Model of Infection |
| Q34795807 | Acinetobacter baumannii: emergence of a successful pathogen |
| Q38008459 | Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models |
| Q28550341 | Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model |
| Q44501175 | Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients |
| Q42050464 | Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii |
| Q46460692 | Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination |
| Q90398183 | Clinical Outcomes Of Colistin In Combination With Either 6-G Sulbactam Or Carbapenems For The Treatment Of Extensively Drug-Resistant Acinetobacter Baumannii Pneumonia With High MIC To Sulbactam, A Prospective Cohort Study |
| Q44944397 | Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000) |
| Q53838114 | Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study. |
| Q34560321 | Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections |
| Q91832701 | Combined Rifampin and Sulbactam Therapy for Multidrug-Resistant Acinetobacter Baumannii Ventilator-Associated Pneumonia in Pediatric Patients |
| Q42256268 | Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia |
| Q53871945 | Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital. |
| Q37330689 | Current control and treatment of multidrug-resistant Acinetobacter baumannii infections |
| Q34109281 | Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection |
| Q43237805 | Diabetic murine models for Acinetobacter baumannii infection |
| Q28554305 | Dynamic Computational Model of Symptomatic Bacteremia to Inform Bacterial Separation Treatment Requirements |
| Q39894808 | Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa |
| Q33676191 | Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii |
| Q59801603 | Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant infection |
| Q35169692 | Experimental models of pulmonary infection |
| Q36095081 | Global challenge of multidrug-resistant Acinetobacter baumannii |
| Q41390340 | Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers |
| Q35076951 | In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii |
| Q36571798 | In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes |
| Q55266483 | In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China. |
| Q100634918 | In vivo bactericidal effect of colistin-linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia |
| Q41625643 | In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases |
| Q37983920 | Inhaled colistin for lower respiratory tract infections. |
| Q35139329 | Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance |
| Q24651466 | Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients |
| Q38058355 | Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens |
| Q59798253 | Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant |
| Q35848861 | Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians |
| Q37636150 | New information about the polymyxin/colistin class of antibiotics |
| Q36994518 | Nosocomial Acinetobacter pneumonia |
| Q36366778 | Nosocomial pneumonia : rationalizing the approach to empirical therapy |
| Q34675017 | Polymyxins as novel and safe mucosal adjuvants to induce humoral immune responses in mice |
| Q37215935 | Polymyxins revisited |
| Q35623068 | Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications |
| Q36047311 | Rapid Direct Method for Monitoring Antibiotics in a Mouse Model of Bacterial Biofilm Infection |
| Q39584788 | Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii. |
| Q46620852 | Successful treatment of Acinetobacter meningitis with meropenem and rifampicin |
| Q36382140 | The epidemiology and control of Acinetobacter baumannii in health care facilities |
| Q34634695 | The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections |
| Q34212044 | The threat from the pink corner |
| Q37099006 | Therapeutic options for Acinetobacter baumannii infections |
| Q38049332 | Therapeutic options for Acinetobacter baumannii infections: an update |
| Q37704397 | Treatment of Acinetobacter infections |
| Q35183740 | Treatment of Acinetobacter spp infections |
| Q44417867 | Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. |
| Q26991886 | Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections |
| Q37058001 | Treatment options for multidrug-resistant Acinetobacter species |
| Q37643643 | Validation of a novel murine wound model of Acinetobacter baumannii infection |
| Q34983666 | Whole transcriptome analysis of Acinetobacter baumannii assessed by RNA-sequencing reveals different mRNA expression profiles in biofilm compared to planktonic cells. |
| Q80972312 | [Recommendations for the treatment of severe nosocomial pneumonia] |
Search more.